# Pinku Mukherjee

> academic, researcher, professor of biological science

**Wikidata**: [Q109981231](https://www.wikidata.org/wiki/Q109981231)  
**Source**: https://4ort.xyz/entity/pinku-mukherjee


## References

1. [University of North Carolina at Charlotte](https://pages.charlotte.edu/pinku-mukherjee/academic-degrees-and-training/)
2. [ORCID Public Data File 2023](https://pub.orcid.org/v3.0/0000-0001-7577-6776/employment/690176)
3. [ORCID iD](https://orcid.org/0000-0001-7577-6776)
4. [Google Scholar](https://scholar.google.com/citations?user=OkBo-hsAAAAJ&hl=en&oi=ao)
5. Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
6. Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer
7. Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice
8. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
9. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma
10. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line
11. A tumor specific antibody to aid breast cancer screening in women with dense breast tissue
12. Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine Mouse Model
13. Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors
14. Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells
15. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer
16. Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population.
17. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma
18. Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis
19. Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling
20. Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma.
21. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer
22. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling
23. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity
24. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma
25. Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice.
26. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.
27. Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model
28. Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis
29. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
30. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma
31. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
32. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways
33. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression
34. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
35. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer
36. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells
37. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
38. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer
39. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model
40. Mucin signature as a potential tool to predict susceptibility to COVID-19
41. Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers
42. uMUC1-Targeting Magnetic Resonance Imaging of Therapeutic Response in an Orthotropic Mouse Model of Colon Cancer
43. Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer
44. Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes
45. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches
46. Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer
47. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells
48. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells
49. APE1 senses DNA single-strand breaks for repair and signaling
50. Microbe-MUC1 Crosstalk in Cancer-Associated Infections